- Home
- WSBF vs AARD Comparison
WSBF vs AARD Comparison
Compare WSBF & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- AARD
- Stock Information
- Founded
- WSBF 1921
- AARD 2017
- Country
- WSBF United States
- AARD United States
- Employees
- WSBF N/A
- AARD N/A
- Industry
- WSBF Savings Institutions
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- WSBF Finance
- AARD Health Care
- Exchange
- WSBF Nasdaq
- AARD Nasdaq
- Market Cap
- WSBF 273.1M
- AARD 231.9M
- IPO Year
- WSBF N/A
- AARD 2025
- Fundamental
- Price
- WSBF $15.19
- AARD $9.99
- Analyst Decision
- WSBF
- AARD Strong Buy
- Analyst Count
- WSBF 0
- AARD 7
- Target Price
- WSBF N/A
- AARD $31.43
- AVG Volume (30 Days)
- WSBF 56.1K
- AARD 177.8K
- Earning Date
- WSBF 10-23-2025
- AARD 11-13-2025
- Dividend Yield
- WSBF 3.94%
- AARD N/A
- EPS Growth
- WSBF 87.32
- AARD N/A
- EPS
- WSBF 1.32
- AARD N/A
- Revenue
- WSBF $137,060,000.00
- AARD N/A
- Revenue This Year
- WSBF N/A
- AARD N/A
- Revenue Next Year
- WSBF N/A
- AARD N/A
- P/E Ratio
- WSBF $11.63
- AARD N/A
- Revenue Growth
- WSBF 2.87
- AARD N/A
- 52 Week Low
- WSBF $11.61
- AARD $4.88
- 52 Week High
- WSBF $16.86
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- WSBF 50.58
- AARD 37.75
- Support Level
- WSBF $15.05
- AARD $9.70
- Resistance Level
- WSBF $15.45
- AARD $12.16
- Average True Range (ATR)
- WSBF 0.34
- AARD 0.83
- MACD
- WSBF 0.01
- AARD -0.28
- Stochastic Oscillator
- WSBF 48.72
- AARD 11.23
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.